Mizuho Raises Amgen Price Target to $388, Keeps Neutral Rating
What happened
Mizuho lifted its price target on Amgen (AMGN) to $388 from $352, per a note published November 20, 2026. The firm maintained its Neutral rating on the shares alongside the target increase. The adjustment comes with AMGN trading at $439.12, above the new target, after a session in which the stock was roughly flat, up 0.06%.
The QL Read
In a risk-off tape (S&P 500 -2.10%, VIX 31.84, breadth 27.1% advancing), Amgen's defensive health care sector gained 0.64% while AMGN's QuantLogix composite sits at 65/100, Neutral. The stock trades 13% above Mizuho's new $388 target, leaving the analyst view below the current market price.
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.